文献速递特殊人群用药

Retosiban治疗自发性早产的II期试点剂量探索研究

Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study.
PubMed 文献 · Br J Clin Pharmacol · 2017-07-11

该研究为三部分、双盲、安慰剂对照、多中心II期试点研究,纳入孕340/7至356/7周自发性早产孕妇29例,随机接受12小时静脉retosiban后单次口服安慰剂(R-P)或12小时静脉安慰剂后单次口服retosiban(P-R)。结果显示retosiban安全耐受性良好,R-P组更多在6小时内达到子宫静止及宫缩减少≥50%,分娩时间延长,但差异无统计学意义。

要点

  • 静脉retosiban在早产孕妇中安全耐受性良好,不良事件不频繁。
  • R-P组6小时子宫静止率63%,P-R组43%,差异无统计学意义。
  • R-P组分娩中位时间26天,P-R组13天,提示可能延长妊娠。

核心结论

  • 静脉retosiban安全耐受性良好,可能延长自发性早产孕妇的妊娠时间。
  • 研究为retosiban进一步疗效评估提供了依据和给药策略。

研究设计与样本

  • 三部分、双盲、安慰剂对照、多中心II期试点剂量探索研究。
  • 共随机29例孕340/7至356/7周自发性早产孕妇,R-P组20例,P-R组9例。
  • A部分随机比例3:1,B部分2:1。

主要发现

  • 不良事件在母亲和新生儿中不频繁,与研究人群预期或混杂因素相关。
  • 口服retosiban吸收迅速,观察到的半衰期为1.45小时。
  • 疗效分析纳入19例:R-P组6小时子宫静止率63%(95%CrI 38,84),P-R组43%(95%CrI 12,78)。
  • R-P组6小时宫缩减少≥50%者63%(95%CrI 38,84),P-R组29%(95%CrI 4,64)。
  • 分娩中位天数R-P组26天,P-R组13天。

临床怎么用

  • 静脉retosiban可作为自发性早产孕妇的安全耐受性选择,可能延长妊娠。
  • 给药策略为12小时静脉retosiban后单次口服安慰剂,或12小时静脉安慰剂后单次口服retosiban。

局限性

  • 样本量小(共29例,疗效分析19例),差异无统计学意义。
  • 为II期试点研究,疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of the present study were to investigate the maternal, fetal and neonatal safety and tolerability, pharmacodynamics and pharmacokinetics of intravenous (IV) retosiban in pregnant women with spontaneous preterm labour (PTL) between 340/7 and 356/7 weeks' gestation. METHODS: In parts A and B of a three-part, double-blind, placebo-controlled, multicentre study, women were randomized 3:1 (Part A) or 2:1 (Part B) to either 12-h IV retosiban followed by a single dose of oral placebo (R-P) or 12-h IV placebo followed by single-dose oral retosiban (P-R). RESULTS: A total of 29 women were randomized; 20 to R-P and nine to P-R. An integrated analysis found that adverse events were infrequent in mothers/newborns and consistent with events expected in the population under study or associated with confounding factors. Retosiban was rapidly absorbed after oral administration, with an observed half-life of 1.45 h. Efficacy analyses included 19 women. While not statistically significant, those receiving R-P more frequently achieved uterine quiescence in 6 h (R-P, 63%; 95% credible interval [CrI]: 38, 84; P-R, 43%; 95% CrI: 12, 78) and more achieved a reduction of ≥50% in uterine contractions in 6 h (R-P, 63%; 95% CrI: 38, 84; P-R, 29%; 95% CrI: 4, 64). The number of days to delivery was increased in women receiving R-P (median 26 days for R-P vs. 13 days for P-R). CONCLUSIONS: Intravenous retosiban has a favourable safety and tolerability profile and might prolong pregnancies in women with PTL. The study provides the rationale and dosing strategy for further evaluation of the efficacy of retosiban in the treatment of PTL.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Thornton S, Valenzuela G, Baidoo C, et al. Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study. Br J Clin Pharmacol. 2017. PMID: 28556962. doi:10.1111/bcp.13336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。